Alpha Tau Announces Acceptance Into FDA’s Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme

Main
News

News

Admin
Oct 21 2024

[Press Release]

Alpha Tau Announces Acceptance Into FDA’s Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme

https://www.globenewswire.com/news-release/2024/10/21/2966203/0/en/Alpha-Tau-Announces-Acceptance-Into-FDA-s-Total-Product-Life-Cycle-Advisory-Program-to-Accelerate-Market-Access-to-Alpha-DaRT-for-Patients-with-Recurrent-Glioblastoma-Multiforme.html

Previous: A year in review: Nano X Imaging Ltd (NNOX)’s performance in the last year Oct 17 2024

Next: Transforming Cardiac Imaging with AI: An Interview with UltraSight Davidi Vortman Feb 07 2025

List